Atrial fibrillation (AFib) affects approximately 6 million Americans and is the leading modifiable risk factor for cardioembolic stroke — yet 30–40% of AFib cases go undiagnosed due to its paroxysmal, often asymptomatic nature. The convergence of consumer wearables and medical-grade ambulatory ECG monitoring has created a new paradigm for opportunistic AFib screening that cardiologists are rapidly integrating into clinical practice.
Consumer Wearables: Apple Watch and Fitbit
The Apple Heart Study (n=419,297) demonstrated that Apple Watch's photoplethysmography (PPG)-based algorithm detected irregular pulse in 0.5% of participants, with 84% confirmed AFib in those receiving ECG patches — high positive predictive value in a low-prevalence population. The FDA-cleared irregular rhythm notification (Apple Watch Series 4+) has sensitivity of 98% and specificity of 98.5% in validation studies. However, PPG-based detection requires the watch to be worn continuously and works best during rest. False positives occur with ectopic beats, poor watch fit, and movement artifact. For clinical follow-up of positive wearable screens, our diagnostic equipment section and cardiac monitoring supplies support in-office ECG confirmation and ambulatory monitoring.
Medical-Grade Options: KardiaMobile and Zio Patch
KardiaMobile 6L (AliveCor): FDA-cleared 6-lead ECG in a credit-card sized device. Clinical sensitivity 93%, specificity 84% for AFib. Advantage: physician-readable ECG strip suitable for documentation. The REHEARSE-AF trial showed KardiaMobile screening detected AFib 3.9× more frequently than usual care in 75+ year-olds over 12 months. Zio Patch (iRhythm): continuous 14-day ambulatory ECG monitoring — the clinical gold standard for paroxysmal AFib detection. Studies show 57% higher diagnostic yield for clinically actionable arrhythmias versus 24-hour Holter monitoring. Our diagnostic equipment section includes clinical ECG supplies and electrode pads supporting cardiac monitoring workflows in outpatient and inpatient settings.
